Advances and directions in chemotherapy using implantable port systems for colorectal cancer: A historical review

Surgery Today

Volumn 44, Issue 8, 2014, Pages 1406-1414

  Inoue, Yasuhiro ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; Implantable port system

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; UFT; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CENTRAL VENOUS PORT SYSTEM; COLORECTAL CANCER; DRUG ADMINISTRATION; HEPATIC ARTERIAL INFUSION; HUMAN; IMPLANTABLE PORT SYSTEM; LIVER METASTASIS; QUALITY OF LIFE; REVIEW; CENTRAL VENOUS CATHETER; COLORECTAL NEOPLASMS; EQUIPMENT DESIGN; HISTORY; INDWELLING CATHETER; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; TRENDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERS, INDWELLING; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EQUIPMENT DESIGN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIVER NEOPLASMS; VASCULAR ACCESS DEVICES;

EID: 84904392777     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-013-0672-8     Document Type: Review

References (82)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
2. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360:1408-17.
3. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779-86. (Pubitemid 350086481)
4. Sawayama H, Hayashi N, Watanabe M, Takamori H, Beppu T, Baba H. The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients. Surg Today. 2012;42:29-34.
5. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The Use of Nitrogen Mustard in the Palliative Treatment of Carcinoma: With Particular Reference to Bronchogenic Carcinoma. J. Cancer, I 1948:634-56.
6. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg. 1950;132:811-32.
7. Donovan TJ. The uses of plastic tubes in the reparative surgery of battle injuries to arteries with and without intra-arterial heparin administration. Ann Surg. 1949;130:1024-43.
8. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-32.
9. Miller TR, Griman OR. Hepatic artery catheterization for liver perfusion. Arch Surg. 1961;82:423-5.
10. Watkins E Jr. Chronometric Infusor - an apparatus for protracted ambulatory infusion therapy. N Engl J Med. 1963;269:850-1.
11. Watkins E Jr, Khazei AM, Nahra KS. Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet. 1970;130:581-605.
12. Sullivan RD, Norcross JW, Watkins E. Chemotherapy by prolonged hepatic-artery infusion. N Engl J Med. 1964;270:321-7.
13. Sullivan RD, Miller E. The clinical effects of prolonged intravenous infusion of 5-fluoro-20 -deoxyuridine. Cancer Res. 1965;25(7):1025-33.
14. Lee M. Regional management of liver metastases. I. Cancer Investig. 1983;1:237-57.
15. Blackshear PJ, Rohde TD, Varco RL, Buchwald H. One year of continuous heparinization in the dog using a totally implantable infusion pump. Surg Gynecol Obstet. 1975;141:176-86.
16. Rohde TD, Blackshear PJ, Varco RL, Buchwald H. Protracted parenteral drug infusion in ambulatory subjects using an implantable infusion pump. Trans Am Soc Artif Intern Organs. 1977;23:13-6. (Pubitemid 9078668)
17. Breedis C, Young C. Blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969-85.
18. Taylor I, Rowling J, West C. Adjuvant cytotoxic liver perfusion for colorectal cancer. Br J Surg. 1979;66:833-7. (Pubitemid 10167776)
19. Swiss Group for Clinical Cancer Research (SAKK) (1995) Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345:349-53.
20. Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet. 1998;351:1677-81. (Pubitemid 28254527)
21. Ensminger WD, Rosowsky A, Raso V. Clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2 deoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Int Med. 1987;107:459-65.
22. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:252-8.
23. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-57.
24. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-6. (Pubitemid 46797946)
25. Kusunoki M, Noda M, Yanagi H, Kotera H, Yamamura T. Second-look hepatectomy after 5FU arterial infusion in patients with primary unresectable hepatic colorectal metastases. Int J Oncol. 1997;10:107-11.
26. Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H. Koisumi J. Surg Today: Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer; 2012.
27. NCI Common Toxicity Criteria Version 2.0 Bethesda, National Cancer Institute, Division of Cancer Treatment, 1999.
28. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol. 1998;16:301-8.
29. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22:3766-75.
30. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808-15. (Pubitemid 27074252)
31. Kusunoki M, Yanagi H, Kotera H, Noda M, Yamamura T. Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5-FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int J Oncol. 1998;13:653-7. (Pubitemid 28435338)
32. Kusunoki M, Yanagi H, Noda M, Yamamura T. The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep. 1999;6:547-52.
33. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001;61:1029-37. (Pubitemid 32174421)
34. Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer. 2000;89:1228-35.
35. Ommaya AK. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet. 1963;2:983-4.
36. Ratcheson RA, Ommaya AK. Experience with the subcutaneous cerebrospinal-fluid reservoir. Preliminary report of 60 cases. N Engl J Med. 1968;279:1025-31.
37. Utz JP. Fungal infections of the central nervous system. Clin Neurosurg. 1966;14:86-100.
38. Rubin RC, Ommaya AK, Henderson ES, Bering EA, Rall DP. Cerebrospinal fluid perfusion for central nervous system neoplasms. Neurology. 1966;16:680-92.
39. Ommaya AK, Rubin RC, Henderson ES, Rall DP, Gieseke FG, Bering EA Jr, et al. A new approach to the treatment of inoperable brain tumors. Med Ann Dist Columbia. 1965;34:455-8.
40. Blackshear PJ, Dorman FD, Blackshear PL Jr, Varco RL, Buchwald H. The design and initial testing of an implantable infusion pump. Surg Gynecol Obstet. 1972;134:51-6.
41. Buchwald H, Grage TB, Vassilopoulos PP, Rohde TD, Varco RL, Blackshear PJ. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer. 1980;45:866-9. (Pubitemid 10129834)
42. Cohen AM, Wood WC, Greenfield A, Waltman A, Dedrick C, Blackshear PJ. Transbrachial hepatic arterial chemotherapy using an implanted infusion pump. Dis Colon Rectum. 1980;23:223-7. (Pubitemid 10083181)
43. Buchwald H, Rohde TD, Dorman FD, Skakoon JG, Wigness BD, Prosl FR, et al. A totally implantable drug infusion device: laboratory and clinical experience using a model with single flow rate and new design for modulated insulin infusion. Diabetes Care. 1980;3:351-8. (Pubitemid 10078136)
44. Skitzki JJ, Chang AE. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol. 2002;11:123-35. (Pubitemid 35279440)
45. Szakacs JG, Szakacs JE, Karl RC. Surgical resection versus perfusion in the treatment of metastatic and primary liver tumors. Ann Clin Lab Sci. 1990;20:245-57. (Pubitemid 20228833)
46. Coombs DW, Fine N. Spinal anesthesia using subcutaneously implanted pumps for intrathecal drug infusion. Anesth Analg. 1991;73:226-31.
47. Kemeny MM. The surgical aspects of the totally implantable hepatic artery infusion pump. Arch Surg. 2001;136:348-52. (Pubitemid 32204975)
48. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996;85:458-67. (Pubitemid 26278029)
49. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685-93. (Pubitemid 18056182)
50. Kemeny MM, Hogan JM, Goldberg DA, Lieu C, Beatty JD, Kokal WA, et al. Continuous hepatic artery infusion with an implantable pump: problems with hepatic artery anomalies. Surgery. 1986;99:501-4. (Pubitemid 16013305)
51. Arai Y, Kamimura N, Suyama K. Amethod to retain subcutaneously the catheter end connected to a new silicon reservoir in intraarterial infusion chemotherapy. Jpn J Cancer Chemother. 1982;9:1838-43.
52. Kumada T, Nakano S. Catheterization for reservoir implantation by puncturing the left axillary artery directly under ultrasound guidance. Nippon Acta Radiol. 1990;12:1617-9.
53. Aubaniac R. Injection intraveineuse sousclaviculaire; advantages et technique. Presse Med. 1952;60:1456.
54. Broviac JW, Cole JJ, Scribner BH. A silicone rubber atrial catheter for prolonged parenteral alimentation. Surg Gynecol Obstet. 1973;136:602-6.
55. Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet. 1979;148:871-5. (Pubitemid 9190337)
56. Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery. 1982;92:706-12. (Pubitemid 13091564)
57. Miura T, Idezuki S, Wada T. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusaid pump. Jpn J Cancer Chemother. 1985;12:1949-61. (Pubitemid 17214989)
58. Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, et al. Management of venous port systems in oncology: a review of current evidence. Ann Oncol. 2008;19:9-15.
59. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complications and failures of subclavian-vein catheterization. N Engl J Med. 1994;331:1735-8.
60. Teichgräber UK, Gebauer B, Benter T, Wagner J. Long-term central venous lines and their complications. Rofo. 2004;176:944-52. (Pubitemid 38937298)
61. Teichgräber UK, Pfitzmann R, Hofmann HA. Central venous port systems as an integral part of chemotherapy. Dtsch Arztebl Int. 2011;108:147-53.
62. Yildizeli B, Laçin T, Batirel HF, Yüksel M. Complications and management of long-term central venous access catheters and ports. J Vasc Access. 2004;5:174-8. (Pubitemid 41158317)
63. Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol. 2009;20:935-40.
64. Ignatov A, Hoffman O, Smith B, Fahlke J, Peters B, Bischoff J, et al. An 11-year retrospective study of totally implanted central venous access ports: complications and patient satisfaction. Eur J Surg Oncol. 2009;35:241-6.
65. Newman KA, Reed WP, Schimpff SC, Bustamante CI, Wade JC. Hickman catheters in association with intensive cancer chemotherapy. Support Care Cancer. 1993;1:92-7.
66. Drakos PE, Nagler A, Or R, Gillis S, Slavin S, Eldor A. Low molecular weight heparin for Hickman catheter-induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation. Cancer. 1992;70:1895-8.
67. Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer. 1983;52:1586-9. (Pubitemid 13018277)
68. Köksoy C, Kuzu A, Erden I, Akkaya A. The risk factors in central venous catheter-related thrombosis. Aust NZ J Surg. 1995;65:796-8.
69. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a doubleblind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005;23:4057-62. (Pubitemid 46211310)
70. Bern M, Lokich J, Sabina R, Bothe A Jr, Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med. 1990;112:423-8. (Pubitemid 20098523)
71. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75:251-3. (Pubitemid 26081476)
72. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized, placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063-9. (Pubitemid 46211311)
73. Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 2005;17:289-96. (Pubitemid 43160120)
74. Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, et al. 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res. 2008;14:2749-55.
75. Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer. 2012;11:263-7.
76. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099-105.
77. Inoue Y, Tanka K, Hiro J, Toiyama Y, Miki C, Kusunoki M. Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer. Oncol Lett. 2010;1:81-5.
78. Inoue Y, Hiro J, Toiyama Y, Tanaka K, Mohri Y, Kusunoki M. Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. Oncol Lett. 2012;3:363-8.
79. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-81. (Pubitemid 28342121)
80. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-72.
81. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042-8.
82. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:141-52.